Study to Find Blood Biomarkers That Differentiate Malignant from Benign Pancreatic Lesions

What this Trial Is About

Researchers are investigating plasma biomarkers that could help distinguish malignant pancreatic lesions from benign ones. Currently, there is no validated blood test to aid in diagnosing pancreatic cancer PDAC, and identifying biomarkers related to the tumor stroma and immune response is a key challenge. The study aims to find biomarkers associated with malignant pancreatic lesions compared to benign pancreatic conditions, ultimately developing a clinical and biological signature to improve diagnosis and treatment decisions. Participants will have a blood sample collected at the start of the study to analyze candidate biomarkers identified from previous work and potentially others. The study compares these biomarkers between patients with malignant pancreatic lesions and those with benign pancreatic lesions, including chronic or acute pancreatitis with suspected precancerous or cystic pancreatic lesions. This is an interventional study involving biological sample collection. During the study, participants will have one visit at baseline when the blood sample is taken. Researchers will evaluate the nature of the pancreatic lesionmalignant or benignbased on imaging tests like radiology and echo-endoscopy, as well as pathological analysis if available. The primary outcome is to assess the lesion status using these methods. Participants involvement is limited to this initial assessment, and the study is sponsored by Centre Hospitalier Universitaire de Besancon, with follow-up care continuing as usual.

Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.